Clinical trial NCT02178696: Predictors of Antidepressant Response
Official title: Predictors of Antidepressant Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Depression
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2014-07-01
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Major depression is a highly prevalent, frequently debilitating illness that too often fails to respond to currently available treatments such as antidepressant medication. Furthermore, randomized controlled trials of antidepressants consistently demonstrate large placebo effects. The investigators hypothesize that individual differences in the function of key brain circuits underlie the observed variability in clinical responses to both placebo and antidepressant medication. This study will test this hypothesis by recruiting treatment-seeking volunteers with major depression, with or without comorbid nicotine dependence. Volunteers will participate in positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scans in the context of a treatment trial in which they will receive both placebo and antidepressant medication. A major goal of the study is to improve prediction of individual clinical responses in future treatment trials in which brain imaging may be unavailable, and to study the mechanisms of antidepressant response in Major Depression.

Detailed description: We performed a single-blinded two-week cross-over randomized controlled trial of two identical oral placebos (described as having either potentially "active" fast-acting antidepressant-like effects or to be "inactive") followed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor (SSRI) or in some cases, another agent as clinically indicated. The volunteers were studied with PET and the µ-opioid receptor selective radiotracer \[11C\]carfentanil after each 1-week "inactive" and "active" oral placebo treatment. In addition, 1 mL of isotonic saline was administered intravenously (i.v.) within sight of the volunteer during PET scanning every 4 min over 20 min only after the 1-week active placebo treatment, with instructions that the compound may be associated with the activation of brain systems involved in mood improvement. This challenge stimulus was utilized to test the individual capacity to acutely activate endogenous opioid neurotransmission under expectations of antidepressant effect.

Eligibility criteria: Inclusion Criteria: Inclusion criteria will include:

* Participants diagnosed with Major Depressive Disorder and will include Hamilton Depressive Rating Scale (HDRS) scores \>15

Exclusion Criteria:

* Comorbid conditions that are medical, neurological or psychiatric, pregnancy, use of hormones (including birth control) or use of psychotropic agents
* We will only permit certain past anxiety disorder diagnoses, including generalized anxiety, panic, agoraphobia, social phobia
* We also will exclude left-handed individuals and patients who have used any centrally acting medications or recreational drugs with the past 2 months
* No history of an implant, pacemaker or pacemaker wires, open heart surgery, artificial heart valve, brain aneurysm surgery, middle ear implant, hearing aid, braces or extensive dental work, cataract surgery or lens implant, implanted mechanical or electrical device, or artificial limb or joint
* No metallic object in their body (such as braces) or have a history of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or other metal fragments

Primary outcomes:
measure: Changes in Mu-opioid Binding Potential During PET
timeFrame: (90 minute PET scans) assessed at Weeks 1 and 2
measure: Changes in BOLD Response During Reward fMRI Task (Monetary Incentive Delay, MID)
timeFrame: (90 minute fMRI scans) assessed at Weeks 1 and 2
Secondary outcomes:
measure: Changes in Dopamine (D 2/3) Binding Potential During PET.
timeFrame: (90 minute PET scan) assessed at Weeks 1 and 2
measure: Changes From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) Score
timeFrame: From Pre to post- active placebo, and from pre to post- inactive placebo (1 week intervention)
measure: Changes From Baseline in PHQ-9 Depression Scores.
timeFrame: From Pre to post- active placebo, and from pre to post- inactive placebo (1 week intervention)
measure: Hamilton Depression Rating Scale Scores
timeFrame: Screening, week 0, week 2, week 4, week 8 and week 10
measure: Montgomery-Asberg Depression Rating Scale
timeFrame: Screening, week 0, week 2, week 4, week 8 and week 10
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Department of Psychiatry
state: Michigan
Study officials:
affiliation: University of Michigan
name: Jon-Kar Zubieta, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pecina M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta JK. Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA Psychiatry. 2015 Nov;72(11):1087-94. doi: 10.1001/jamapsychiatry.2015.1335.
citation: Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Pecina M. Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan;1(1):68-76. doi: 10.1016/j.bpsc.2015.10.002.